Home » Stocks » XXII

22nd Century Group, Inc. (XXII)

Stock Price: $3.29 USD -0.06 (-1.79%)
Updated Mar 1, 2021 4:00 PM EST - Market closed
Market Cap 461.01M
Revenue (ttm) 28.06M
Net Income (ttm) -19.50M
Shares Out 138.86M
EPS (ttm) -0.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $3.29
Previous Close $3.35
Change ($) -0.06
Change (%) -1.79%
Day's Open 3.42
Day's Range 3.25 - 3.52
Day's Volume 2,812,860
52-Week Range 0.55 - 4.66

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Schaeffers Research - 1 month ago

Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry...

Other stocks mentioned: ACB, APHA, ARNA, HUGE, IIPR, TLRY, YCBD
GlobeNewsWire - 1 month ago

New space is ideally equipped and located in the heart of Buffalo's urban renewal New space is ideally equipped and located in the heart of Buffalo's urban renewal

GlobeNewsWire - 1 month ago

The FDA Can Save 8 Million Lives and Prevent 1,600 Kids From Becoming Addicted Every Day The FDA Can Save 8 Million Lives and Prevent 1,600 Kids From Becoming Addicted Every Day

GlobeNewsWire - 1 month ago

WILLIAMSVILLE, N.Y., Jan. 19, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, v...

GlobeNewsWire - 1 month ago

Company will significantly increase planting in the 2021 crop year Company will significantly increase planting in the 2021 crop year

GlobeNewsWire - 2 months ago

New intellectual property facilitates the precise control and modulation of cannabinoid production New intellectual property facilitates the precise control and modulation of cannabinoid produ...

Zacks Investment Research - 2 months ago

Investors need to pay close attention to 22nd Century (XXII) stock based on the movements in the options market lately.

Zacks Investment Research - 2 months ago

Investors need to pay close attention to 22nd Century (XXII) stock based on the movements in the options market lately.

Seeking Alpha - 2 months ago

There are reasons to believe that the company will receive MRTP status, which enables the company to be the only company to sell and market VLN cigarettes. While investors have already piled i...

GlobeNewsWire - 2 months ago

The Company's Research Cigarettes Continue to Fuel Studies Adding to the Vast Body of Research Supporting a National Nicotine Standard for Combustible Cigarettes The Company's Research Cigaret...

GlobeNewsWire - 3 months ago

WILLIAMSVILLE, N.Y., Nov. 18, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII ), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, ...

GlobeNewsWire - 3 months ago

WILLIAMSVILLE, N.Y., Nov. 16, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, v...

Zacks Investment Research - 3 months ago

Investors need to pay close attention to 22nd Century (XXII) stock based on the movements in the options market lately.

Schaeffers Research - 3 months ago

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks last week and we will look ahead at the pot stocks to...

Other stocks mentioned: CGC, APHA, CRON, GWPH, IIPR, NTEC, VFF, YCBD
Seeking Alpha - 3 months ago

22nd Century Group, Inc. (XXII) CEO James Mish on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

22nd Century (XXII) delivered earnings and revenue surprises of 25.00% and 32.91%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 3 months ago

Key Highlights:

Zacks Investment Research - 4 months ago

22nd Century (XXII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

WILLIAMSVILLE, N.Y., Oct. 22, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, life science company driven by next generation biotechnology, will...

GlobeNewsWire - 4 months ago

The U.S. Food and Drug Administration to provide an update on the Agency's Comprehensive Plan for Tobacco and Nicotine Regulation The U.S. Food and Drug Administration to provide an update on ...

Zacks Investment Research - 4 months ago

22nd Century (XXII) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

GlobeNewsWire - 4 months ago

New intellectual property leads to precise genetic control over nicotine levels in virtually any variety of the tobacco plant New intellectual property leads to precise genetic control over ni...

GlobeNewsWire - 5 months ago

WILLIAMSVILLE, N.Y., Sept. 24, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant-based, life science company driven b...

GlobeNewsWire - 6 months ago

WILLIAMSVILLE, N.Y., Aug. 27, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant-based life science company driven by ...

Seeking Alpha - 6 months ago

22nd Century Group, Inc. (XXII) CEO Jim Mish on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

Key Highlights:

Benzinga - 8 months ago

22nd Century Group, Inc. Common Stock Inc (AMEX:XXII) was trading 2.4% higher from the previous closing price.

GlobeNewsWire - 8 months ago

Mish brings extensive global executive leadership experience in the development, manufacturing and commercialization of active pharmaceutical ingredients, including cannabinoids, and related c...

Seeking Alpha - 9 months ago

22nd Century Group, Inc. (XXII) Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 10 months ago

22nd Century Group achieves another important milestone in the FDA’s scientific review of the Company’s MRTP application for its reduced nicotine content cigarettes 22nd Century Group achieves...

GlobeNewsWire - 10 months ago

Williamsville, NY, April 08, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant biotechnology company focused on reduc...

GlobeNewsWire - 11 months ago

Delivers Complete High-Quality Hemp/Cannabis Genome Sequence; Establishes New Proprietary Hemp/Cannabis Bioinformatics Platform

GlobeNewsWire - 11 months ago

New Vice President of Acquisitions and New Director of Communications & Investor Relations Set to Drive Acquisition Efforts and Improve Investor Engagement New Vice President of Acquisitions a...

GlobeNewsWire - 11 months ago

Congressman Pallone Urges FDA to Move Forward with Proposal to Limit Nicotine in All Cigarettes Congressman Pallone Urges FDA to Move Forward with Proposal to Limit Nicotine in All Cigarettes

GlobeNewsWire - 11 months ago

Congressman Pallone Urges FDA to Move Forward with Proposal to Limit Nicotine in All Cigarettes Congressman Pallone Urges FDA to Move Forward with Proposal to Limit Nicotine in All Cigarettes

GlobeNewsWire - 1 year ago

Williamsville, NY, Jan. 13, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicoti...

GlobeNewsWire - 1 year ago

Meeting is next official step toward possible marketing authorization for 22nd Century Group’s VLN® product in the United States Meeting is next official step toward possible marketing authori...

GlobeNewsWire - 1 year ago

FDA determines that sale of product in the U.S. is ‘appropriate for the protection of the public health’ FDA determines that sale of product in the U.S. is ‘appropriate for the protection of t...

GlobeNewsWire - 1 year ago

Williamsville, NY, Dec. 13, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicoti...

Benzinga - 1 year ago

22nd Century Group Inc (NYSE: XXII) a plant biotechnology company focused on tobacco and cannabis plant research, on Wednesday announced the initial closing of an investment in Panacea Life Sc...

GlobeNewsWire - 1 year ago

Investment provides platform to commercialize 22nd Century’s unique hemp/cannabis plant lines in development and leverage strengths in consumer-packaged-goods and FDA-regulatory affairs Invest...

The Motley Fool - 1 year ago

Which stock wins in a matchup between these two cannabis-focused biotechs?

Other stocks mentioned: GWPH
The Motley Fool - 1 year ago

Put in another context, these are the only six pot stocks that rose last month.

Other stocks mentioned: ACRGF, CGC, IIPR, NXTTF, STZ, STZ.B, TCNNF
The Motley Fool - 1 year ago

Last month was a rough one for most pot stocks. But these three managed to deliver gains despite the overall malaise.

Other stocks mentioned: IIPR, NXTTF
The Motley Fool - 1 year ago

Despite another miserable month for marijuana stocks, these companies managed to buck the trend.

Other stocks mentioned: APHA, CBWTF, CRLBF, ORHOF, SHOP, STZ, TGODF, TRSSF, ZYNE
The Motley Fool - 1 year ago

Most pot stocks performed poorly last month, but not these three highfliers.

Other stocks mentioned: APHA, TGODF
GuruFocus - 1 year ago

President and CEO of 22nd Century Group Inc (30-Year Financial, Insider Trades) Clifford B Fleet (insider trades) bought 100,000 shares of XXII on 08/27/2019 at an average price of $1.9 a share.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor 22nd Century Group.

Seeking Alpha - 1 year ago

22nd Century Group's tobacco business still looks like a big ball of problems.

Seeking Alpha - 1 year ago

22nd Century Group, Inc. (XXII) CEO Cliff Fleet on Q2 2019 Results - Earnings Call Transcript

About XXII

22nd Century Group, a plant biotechnology company, provides technology that allows to alter the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. The company offers SPECTRUM research cigarettes for use in independent clinical studies; and very low nicotine content (VLNC) tobacco cigarettes under the Moonlight and Moonlight Menthol brands. It is also involved in contract manufacturing business for third-party branded tobacco products. The co... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
1998
Stock Exchange
NYSEAMERICAN
Ticker Symbol
XXII
Full Company Profile

Financial Performance

In 2019, XXII's revenue was $25.83 million, a decrease of -2.25% compared to the previous year's $26.43 million. Losses were -$26.56 million, 233.4% more than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for XXII stock is "Strong Buy" and the 12-month stock price forecast is 7.00.

Price Target
$7.00
Analyst Consensus: Strong Buy